Semma Therapeutics

company

About

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$44M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
51 - 100
Operating Status
Active

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$158M
Semma Therapeutics has raised a total of $158M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 29, 2017 Series B $114M 2 Detail
Mar 23, 2017 Series Unknown 1 Detail
Mar 24, 2015 Series A $44M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Semma Therapeutics is funded by 2 investors. Medtronic and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Medtronic Series B
ARCH Venture Partners Series B